Third Quarter Results Announced by Osiris Therapeutics

Osiris Therapeutics (NASDAQ:OSIR) has announced its third quarter financial results for 2015.
Some of the highlights from the press release are:

• Reported product revenue for the quarter of $24.3 million.
• Obtained coverage of Grafix^® for 128 million lives, an increase of 5 million lives compared to the previous quarter.
• Initiated a Phase III clinical study for OTI-15-01 for the treatment of Diabetic Foot Ulcers. The next phase of the Biological License program for OTI-15-01 is to pursue a clinical indication for Venous Leg Ulcers.
• Launched two new products: TruSkin^™ and Stravix^™. These products will provide solutions to wound specialists and surgeons for the treatment of larger wounds and surgical reconstruction procedures.
• Continued to invest in our market access, finance and manufacturing departments. Osiris has also completed the transition from external vendor hotline services support to an Osiris Therapeutics Reimbursement Hotline and Insurance Verification Department supporting all company product lines and added additional resources to the finance and manufacturing teams. The management team was strengthened with the appointment of Greg Law as Chief Financial Officer and Dwayne Montgomery as Chief Business Officer.
• Completed the quarter with loss from continuing operations of $842,000 and with $102.4 million in total assets.

Click here to read the full press release.